[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 244
Citations 0
News From the Centers for Disease Control and Prevention
October 16, 2013

CDC Offers Investigational Drug

JAMA. 2013;310(15):1553. doi:10.1001/jama.2013.278652

The Centers for Disease Control and Prevention (CDC) now has an expanded-access investigational new drug protocol in effect with the US Food and Drug Administration to make miltefosine directly available to treat infections caused by free-living amebae (FLA).

The infections include primary amebic meningoencephalitis caused by Naegleria fowleri and granulomatous amebic encephalitis caused by Balamuthia mandrillaris and Acanthamoeba species. Even with combination treatment with drugs that have in vitro activity against FLA, the mortality rate from these infections exceeds 90%.

First Page Preview View Large
First page PDF preview
First page PDF preview
×